Protective effect of bivalent HPV vaccination in 9 246 women with high-risk human papillomavirus infection / 公共卫生与预防医学

ABSTRACT

Objective To analyse the high-risk human papilloma virus (HPV) infection in women, and to analyze the protective effect of bivalent HPV vaccine on HPV infection. Methods A case-control study method was used to retrospectively investigate the HPV infection status of 9246 women who received high-risk HPV infection examination in the outpatient department of Shiyan people's Hospital of Hubei from January 2018 to December 2018. The second-generation hybrid capture method and colposcopy examination were used to diagnose. Using a 11 matching method, the uninfected individuals who were examined during the same period were taken as the control group, and the confirmed infected group was taken as the case group, and the differences in the vaccination rates of the bivalent HPV vaccine between the two groups were compared. At the same time, the case group was divided into two groups according to the vaccinated and unvaccinated groups and followed up. The events ranged from 24 to 36 months. The incidence of persistent HPV infection, cervical intraepithelial neoplasia (CIN) and cervical cancer were counted to understand Protective effect of bivalent HPV vaccination against HPV infection in a high-risk female population. Results A total of 1 632 cases (17.65%) of 9 246 women were screened positive for high-risk HPV infection. Chi-square results showed that the HPV positive infection rate of rural women (32.84%) was lower than that of urban women (67.16%). , Marital status also has a certain influence on HPV infection. Among the 1632 cases of HPV positive infection, 629 cases (38.54%) were vaccinated with bivalent HPV vaccine, and 1003 cases (61.46%) were not vaccinated with bivalent HPV vaccine. During the follow-up period of 24-36 months, the vaccination group finally obtained follow-up data of 584 cases due to unwillingness to cooperate (18 cases), unable to conduct research due to organic changes (24 cases), and mental disorders (3 cases), with a loss to follow-up rate of 7.15 cases. %; In the unvaccinated group, 949 cases of follow-up data were finally obtained due to change of residence (32 cases), low degree of cooperation (20 cases) and psychological factors (2 cases), and the loss to follow-up rate was 5.38%. The results after follow-up showed that the persistent HPV infection rate in the bivalent HPV vaccination group, the positive rate of high-risk HPV infection at the last follow-up, the cumulative incidence of CIN1 during the follow-up period, the cumulative incidence of CIN2+ during the follow-up period, the incidence of CIN1 at the last follow-up, and the incidence of CIN2+ at the last follow-up. and cervical cancer incidence rates were 3.07%, 0.82%, 1.84%, 1.02%, 0.82%, 0.20%, and 0.00%, respectively, and the bivalent HPV unvaccinated groups were 12.91%, 15.52%, 7.14%, 4.40%, and 3.02%, respectively. , 1.37% and 0.27%. Persistent HPV infection rate, positive rate of high-risk HPV infection at last follow-up, cumulative incidence of CIN1 during follow-up, cumulative incidence of CIN2+ during follow-up, incidence of CIN1 at last follow-up, and incidence of CIN2+ at last follow-up were significantly lower in bivalent HPV vaccination group in the control group (P<0.05). Conclusion Bivalent HPV vaccination has an important protective effect on HPV persistent infection, cervical lesions and cervical cancer in high-risk women.